ReviewHematology/oncology clinics of North America2013
Chronic granulomatous disease.
Review in Hematology/oncology clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 345 citations in OpenAlex.
- Trends and collaborations in discoid lupus erythematosus research: a bibliometric analysis from 2010 to 2024.Frontiers in medicine · 2025Pooled it
- Host genetic susceptibility to mycetoma.PLoS neglected tropical diseases · 2020Pooled it
- A skin-deep mystery in a patient with chronic granulomatous disease.JAAD case reports · 2026Article
- Transient Phagocytic Dysfunction Mimicking Chronic Granulomatous Disease: A Rare Complication in Delayed Transverse Rectus Abdominis Myocutaneous Flap Breast Reconstruction.Plastic and reconstructive surgery. Global open · 2026Article
- Chronic granulomatous disease: Clinical, microbial, and genetic findings in 39 Colombian patients.Journal of human immunity · 2026Article
- Bursting at the Seams.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Clinical features, genotypes, and geographic distribution of 238 Latin American CGD patients.Journal of human immunity · 2025Article
- Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-γ Treatment Efficacy.Journal of clinical immunology · 2025Article
- Chronic Granulomatous Disease: A Multicentre Study of DHR Flow Cytometry Results and Clinical Correlations in Malaysia.The Malaysian journal of medical sciences : MJMS · 2025Article
- Tuberculosis Presenting as a Patchy Consolidation in a Young Patient With Chronic Granulomatosis Disease.Clinical case reports · 2025Article
- Diagnosis of Chronic Granulomatous Disease: Strengths and Challenges in the Genomic Era.Journal of clinical medicine · 2024Review
- Structural basis for EROS binding to human phagocyte NADPH oxidase NOX2.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Redox Pathogenesis in Rheumatic Diseases.ACR open rheumatology · 2024Review
- Novel mutations in CYBB Gene Cause X-linked chronic Granulomatous Disease in Pakistani patients.Italian journal of pediatrics · 2023Article
- Immunity to fungi in the lung.Seminars in immunology · 2023Review
- The formation and function of the neutrophil phagosome.Immunological reviews · 2023Review
- Granulomatous inflammation in inborn errors of immunity.Frontiers in pediatrics · 2023Review
- Chronic granulomatous disease in the United Arab Emirates: clinical and molecular characteristics in a single center.Frontiers in immunology · 2023Article
- Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.Frontiers in immunology · 2023Review
- Immunogenetics associated with severe coccidioidomycosis.JCI insight · 2022Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Chronic granulomatous disease (CGD) is a paradigm for nonlymphoid primary immune defects, and has guided elucidation of oxygen metabolism in the phagocyte, vasculature, and brain. It has been in the forefront of the development of antimicrobial prophylaxis before the advent of advanced HIV and before its routine use in neutropenia. It has been an attractive target for gene therapy and bone marrow transplantation for nonmalignant diseases. Therefore, CGD is worthy of attention for its historical interest and because it is a disease for which expert management is imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.